Levothyroxine Recall 2026: Nationwide Subpotent Thyroid Medication Recall Issued by Major Pharmaceuticals

Published: July 29, 2026 | Category: FDA Drug Recalls / Health News

FDA Class II Recall Alert: Major Pharmaceuticals has voluntarily recalled specific lots of levothyroxine sodium tablets due to subpotency. Patients taking thyroid medication for hypothyroidism should check lot numbers immediately.

In a major development for millions of Americans managing hypothyroidism, Major Pharmaceuticals has issued a nationwide levothyroxine recall 2026. The U.S. Food and Drug Administration (FDA) classified the action as a Class II recall after the company initiated the recall on July 13, 2026. The FDA formalized the classification around July 17, 2026.

The recalled product is levothyroxine sodium tablets, a prescription thyroid hormone replacement used to treat hypothyroidism, goiter, Hashimoto’s disease, and certain thyroid cancers. The reason for the recall is subpotency — the tablets contain less active ingredient than listed on the label, making them less effective.

Why This Thyroid Medication Was Recalled

Routine stability testing revealed that certain lots of levothyroxine sodium tablets failed potency (assay) specifications. A subpotent thyroid medication may deliver a lower dose than prescribed, potentially allowing hypothyroidism symptoms such as fatigue, weight gain, cold intolerance, constipation, dry skin, or depression to return or worsen.

According to the FDA, the probability of serious or permanent harm is remote. This is why the agency designated the thyroid drug recall as Class II — meaning use of the product may cause temporary or medically reversible adverse health consequences.

Some of the recalled products were also distributed by Cardinal Health. Shipping of the affected lots began as early as January 2025.

Which Levothyroxine Sodium Tablets Are Affected?

This levothyroxine sodium tablets recall does not affect every brand or strength of thyroid medication. Only specific lots packaged and distributed by Major Pharmaceuticals (and some by Cardinal Health) are included.

Affected strengths range from 25 mcg to 150 mcg and were primarily sold in unit-dose blister packaging (100-tablet cartons of 10×10 blisters or individual 10-tablet packs).

Recalled Lot Numbers and Expiration Dates

• 25 mcg – Lot N02212 (Expires July 2026) – NDC 0904-6949-61
• 50 mcg – Lot N02200 (Expires October 2026) – NDC 0904-6950-61
• 75 mcg – Lots N02172 (July 2026), N02296 & N02288 (December 2026) – NDC 0904-6951-61
• 88 mcg – Lot N02310 (Expires January 2027) – NDC 0904-6952-61
• 112 mcg – Lot N02203 (Expires September 2026) – NDC 0904-6954-61
• 125 mcg – Lot N02266 (Expires November 2026) – NDC 0904-6955-61
• 150 mcg – Lot N02167 (Expires July 2026) – NDC 0904-6956-61

Additional Cardinal Health blister packs share corresponding lot numbers (e.g., bag lots N02212A/B, N02200A/B, etc.). Always verify the exact lot number printed on your package.

What Patients Should Do About the Levothyroxine Recall

1. Check the lot number and expiration date on your current bottle or blister pack against the list above.
2. If your medication matches a recalled lot, contact your pharmacist or healthcare provider right away.
3. Do not stop taking levothyroxine abruptly unless directed by a doctor — sudden discontinuation can be dangerous.
4. Return the affected product to the pharmacy for a replacement with an unaffected lot or alternative manufacturer.
5. Monitor for returning symptoms of hypothyroidism and report any concerns to your physician.
6. Adverse events can be reported to the FDA through the MedWatch program.

Unaffected lots and other brands of levothyroxine remain available and safe for continued use.

Understanding the Impact of a Subpotent Thyroid Medication Recall

Levothyroxine requires precise dosing. Even small reductions in potency can disrupt hormone levels in sensitive patients. This is why the FDA and manufacturers treat potency failures seriously, even when the overall health risk is considered moderate.

Patients with hypothyroidism should remain vigilant about future FDA recalls thyroid medication announcements and always confirm the manufacturer and lot number when refilling prescriptions.

Key Takeaways

• A nationwide levothyroxine recall 2026 is in effect for select Major Pharmaceuticals lots due to subpotency.
• The FDA classified it as a Class II recall.
• Only specific lot numbers and strengths are affected — not all thyroid medication.
• Check your medication immediately and consult your pharmacist or doctor for replacement if needed.
• Never stop thyroid medication without medical guidance.

For the most current information, refer to the official FDA Enforcement Report or contact your healthcare provider. Stay informed to protect your thyroid health.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional regarding medication recalls and treatment decisions.

Keywords covered: levothyroxine recall 2026, subpotent thyroid medication recall, levothyroxine hypothyroidism medication recall, thyroid medication recall, levothyroxine, levothyroxine recall, fda recalls thyroid medication, thyroid drug recall, thyroid medication recalled, levothyroxine sodium tablets recall